CN101340934B - 免疫rna构建体 - Google Patents
免疫rna构建体 Download PDFInfo
- Publication number
- CN101340934B CN101340934B CN2006800479378A CN200680047937A CN101340934B CN 101340934 B CN101340934 B CN 101340934B CN 2006800479378 A CN2006800479378 A CN 2006800479378A CN 200680047937 A CN200680047937 A CN 200680047937A CN 101340934 B CN101340934 B CN 101340934B
- Authority
- CN
- China
- Prior art keywords
- cell
- compound
- nucleic acid
- aptamers
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Description
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112660A EP1800695A1 (en) | 2005-12-21 | 2005-12-21 | Immuno-RNA-constructs |
EP05112660.5 | 2005-12-21 | ||
PCT/EP2006/070116 WO2007071777A2 (en) | 2005-12-21 | 2006-12-21 | Immuno-rna-constructs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101340934A CN101340934A (zh) | 2009-01-07 |
CN101340934B true CN101340934B (zh) | 2013-04-24 |
Family
ID=36646002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800479378A Expired - Fee Related CN101340934B (zh) | 2005-12-21 | 2006-12-21 | 免疫rna构建体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8829178B2 (zh) |
EP (2) | EP1800695A1 (zh) |
CN (1) | CN101340934B (zh) |
CA (1) | CA2633776C (zh) |
DK (1) | DK1976564T3 (zh) |
HK (1) | HK1123728A1 (zh) |
WO (1) | WO2007071777A2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008015195A (es) * | 2006-06-01 | 2009-01-26 | Univ Duke | Metodo de suministro. |
US10842642B2 (en) | 2009-04-16 | 2020-11-24 | Nuvasive, Inc. | Methods and apparatus of performing spine surgery |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US20130245102A1 (en) * | 2010-10-12 | 2013-09-19 | Research Foundation Of The City University Of New York | Novel dna templates for small rna production in mammalian cells |
US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
CA2880833A1 (en) * | 2012-08-03 | 2014-02-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
WO2014030147A2 (en) * | 2012-08-23 | 2014-02-27 | Fundación Fraunhofer Chile Research | Synthetic proteins based on dendrimers |
US10711272B2 (en) * | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
US10687956B2 (en) | 2014-06-17 | 2020-06-23 | Titan Spine, Inc. | Corpectomy implants with roughened bioactive lateral surfaces |
BR112017012377A2 (pt) * | 2014-12-09 | 2018-04-24 | Abbvie Inc | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula |
AU2016355581B2 (en) | 2015-11-20 | 2022-09-08 | Titan Spine, Inc. | Processes for additively manufacturing orthopedic implants |
TWI726940B (zh) | 2015-11-20 | 2021-05-11 | 美商泰坦脊柱股份有限公司 | 積層製造整形外科植入物之方法 |
TW202304996A (zh) | 2016-06-08 | 2023-02-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
EP3493769B1 (en) | 2016-08-03 | 2022-03-30 | Titan Spine, Inc. | Titanium implant surfaces free from alpha case and with enhanced osteoinduction |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU648313B2 (en) * | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
US5912170A (en) * | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
US5439819A (en) * | 1993-08-27 | 1995-08-08 | The Regents Of The University Of California | Chimeric protein tyrosine kinases |
US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5935835A (en) * | 1996-10-11 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotide encoding human Myt-1 kinase clone |
EP0973935A2 (en) * | 1997-03-20 | 2000-01-26 | Variagenics, Inc. | Target genes for allele-specific drugs |
US6346406B1 (en) * | 1997-08-20 | 2002-02-12 | University Of Medicine & Dentistry Of New Jersey | Elongation factor-2 kinase (EF-2 kinase), and methods of use therefor |
US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
WO2001001137A1 (en) * | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
WO2002094185A2 (en) * | 2001-05-18 | 2002-11-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
AU4674101A (en) * | 2000-04-12 | 2001-10-23 | Implyx Ltd. | Compositions for drug delivery |
EP1283719B1 (de) | 2000-04-22 | 2007-09-05 | PharmedArtis GmbH | Apoptotika |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US7109165B2 (en) * | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
WO2003007889A2 (en) * | 2001-07-17 | 2003-01-30 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
AU2003213047A1 (en) | 2002-02-13 | 2003-09-04 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
EP1741781A3 (en) * | 2002-02-20 | 2007-06-06 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20060292651A1 (en) | 2002-10-03 | 2006-12-28 | Alexandre Juillerat | Protein labelling with oº-alkylguanine-dna alkyltrnsferase |
WO2004044141A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
DE60332277D1 (de) | 2002-11-26 | 2010-06-02 | Univ Massachusetts | Verabreichung von sirnas |
WO2004078215A2 (en) | 2003-02-28 | 2004-09-16 | The Board Of Trustees Of The University Of Illinois | Use of antibody conjugated deoxycytidine kinase for adept |
CN1826527B (zh) | 2003-05-23 | 2010-11-24 | 瑞士联邦理工大学.洛桑(Epfl) | 基于酰基载体蛋白的蛋白标记方法 |
EP1675949A2 (en) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050148535A1 (en) * | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
JP2007513968A (ja) | 2003-12-12 | 2007-05-31 | ウイスコンシン アラムニ リサーチ ファンデーション | 哺乳動物神経細胞へのsiRNAのデリバリー |
US8163479B2 (en) | 2004-03-02 | 2012-04-24 | Ecole Polytechnique Federale De Lausanne | Specific substrates for O6-alkylguanine-DNA alkyltransferase |
EP1737879B1 (en) * | 2004-04-19 | 2012-10-10 | Archemix LLC | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
WO2006021553A1 (en) | 2004-08-23 | 2006-03-02 | Covalys Biosciences Ag | Method for protein purification and labeling based on a chemoselective reaction |
WO2006114409A1 (en) | 2005-04-27 | 2006-11-02 | Covalys Biosciences Ag | Pyrimidines reacting with o6-alkylguanine-dna alkyltransferase |
KR20080066987A (ko) | 2005-11-04 | 2008-07-17 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | siRNA에 대한 전달 운반체로서의 펩티드-다이서 기질RNA 접합체들 |
EP1882688A1 (en) | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
-
2005
- 2005-12-21 EP EP05112660A patent/EP1800695A1/en not_active Withdrawn
-
2006
- 2006-12-21 EP EP06841574.4A patent/EP1976564B1/en not_active Not-in-force
- 2006-12-21 US US12/086,817 patent/US8829178B2/en not_active Expired - Fee Related
- 2006-12-21 WO PCT/EP2006/070116 patent/WO2007071777A2/en active Application Filing
- 2006-12-21 CN CN2006800479378A patent/CN101340934B/zh not_active Expired - Fee Related
- 2006-12-21 DK DK06841574.4T patent/DK1976564T3/en active
- 2006-12-21 CA CA2633776A patent/CA2633776C/en not_active Expired - Fee Related
-
2009
- 2009-04-03 HK HK09103177.0A patent/HK1123728A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
Also Published As
Publication number | Publication date |
---|---|
CA2633776C (en) | 2018-03-06 |
EP1800695A1 (en) | 2007-06-27 |
CA2633776A1 (en) | 2007-06-28 |
DK1976564T3 (en) | 2016-06-06 |
US20090304717A1 (en) | 2009-12-10 |
US8829178B2 (en) | 2014-09-09 |
EP1976564B1 (en) | 2016-02-24 |
CN101340934A (zh) | 2009-01-07 |
HK1123728A1 (en) | 2009-06-26 |
EP1976564A2 (en) | 2008-10-08 |
WO2007071777A3 (en) | 2007-11-22 |
WO2007071777A2 (en) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101340934B (zh) | 免疫rna构建体 | |
Fu et al. | Aptamers, the nucleic acid antibodies, in cancer therapy | |
Meyer et al. | Cell-specific aptamers as emerging therapeutics | |
JP5362350B2 (ja) | 小分子活性化rna分子及び使用方法 | |
Subramanian et al. | Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer | |
Mayer | The chemical biology of aptamers | |
CN107614685B (zh) | Rna纳米颗粒及其使用方法 | |
McNamara et al. | Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice | |
CN109963564A (zh) | 用于核酸递送的解体型细胞穿透性复合物 | |
CN104854243B (zh) | 用于检测癌症干细胞的EpCAM适配子 | |
KR101511183B1 (ko) | siRNA의 타겟된 운반 | |
JP4505749B2 (ja) | Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物 | |
CA2768598A1 (en) | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes | |
Xue et al. | Synergistic targeting HER2 and EGFR with bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth | |
CN108289906A (zh) | 抗肿瘤性药物递送制剂 | |
Zavoiura et al. | Nanobody–siRNA conjugates for targeted delivery of siRNA to cancer cells | |
US20090202623A1 (en) | Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent | |
CN106794216A (zh) | 阻断异粘蛋白‑snd1相互作用的肽作为癌症治疗的用途 | |
KR20110083919A (ko) | 복합 유전자를 표적하는 siRNA 다중 접합체 및 이의 제조방법 | |
US10023864B2 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | |
LT et al. | IMMUNO-RNA KONJUGATE IMMUNO-RNA CONJUGUES | |
US20240043846A1 (en) | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | |
US20220251561A1 (en) | Eph2a aptamer and uses thereof | |
Kelly | Aptamer directed delivery via cell surface receptors | |
WO2022104006A2 (en) | Gpc3 aptamers and variants and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1123728 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1123728 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Munich, Germany Patentee after: Fraunhofer Application and Research Promotion Association Address before: Munich, Germany Patentee before: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20191221 |